Peripheral Vasodilator Drugs Market Report 2026

The peripheral vasodilator drugs market size has grown strongly in recent years. It will grow from $6.61 billion in 2025 to $6.99 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of hypertension, increased incidence of peripheral vascular diseases, long-term clinical use of nitrates and calcium channel blockers, growing cardiovascular disease burden, expanding hospital-based cardiovascular treatment.

The peripheral vasodilator drugs market size is expected to see strong growth in the next few years. It will grow to $8.56 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging global population, rising cases of heart failure and angina, growing demand for outpatient cardiovascular management, increasing adoption of generic vasodilator drugs, improved diagnosis of peripheral circulation disorders. Major trends in the forecast period include growing use of vasodilators in chronic hypertension management, increased preference for combination cardiovascular therapies, rising adoption of long-acting vasodilator formulations, expansion of peripheral vasodilator use in heart failure care, shift toward improved safety and tolerability profiles.

An increase in the prevalence of cardiovascular diseases is anticipated to drive the growth of the peripheral vasodilator drug market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders that affect the heart and blood vessels, often resulting from atherosclerosis, and can lead to conditions such as heart attacks, strokes, hypertension, and heart failure. The occurrence of cardiovascular diseases is primarily influenced by sedentary lifestyles, unhealthy diets, aging populations, rising obesity rates, and associated health conditions like diabetes and hypertension. Peripheral vasodilators help in cardiovascular diseases by improving blood circulation, lowering blood pressure, reducing the heart’s workload, and relieving symptoms of conditions such as peripheral arterial disease. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease was responsible for 919,032 deaths in 2023, representing one in every three deaths. Coronary heart disease continued to be the most common form of heart disease, and notably, approximately one in six deaths from cardiovascular diseases occurred in adults younger than 65 years. Consequently, the rising prevalence of cardiovascular diseases is propelling the growth of the peripheral vasodilator drug market.

The growth of the peripheral vasodilator drug market is expected to be driven by the increasing geriatric population in the coming years. The geriatric population refers to individuals typically aged 65 years and above, representing older adults with distinct healthcare, social, and physiological needs associated with aging. This population is growing primarily due to rising life expectancy, which allows more people to live longer as a result of improved healthcare, better disease management, and enhanced living conditions. Peripheral vasodilator drugs support the geriatric population by enhancing blood flow to aging tissues, aiding in the management of age-related circulatory disorders, and reducing complications linked to decreased vascular elasticity. For example, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration reported that in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is expected to increase to 22.1 million by 2072, accounting for 27% of the population. Consequently, the growing geriatric population is contributing to the expansion of the peripheral vasodilator drug market.

Major companies operating in the peripheral vasodilator drugs market are concentrating on the development of triple-drug combination therapies to enhance treatment outcomes and increase their market presence in cardiovascular therapeutics. Triple-drug combination therapy is an antihypertensive fixed-dose combination (FDC) designed for patients who have not achieved sufficient blood pressure control with dual-drug therapies or cannot tolerate diuretic-based combinations. For example, in August 2023, Ajanta Pharma Limited, an India-based pharmaceutical company with a focus on cardiology, launched Met XL AMT, a new triple-drug combination to treat hypertension in Indian patients. It is a fixed-dose combination of three antihypertensive agents: Telmisartan, Amlodipine, and Metoprolol. These agents work synergistically to lower blood pressure by relaxing blood vessels, a key feature of peripheral vasodilators. The medication has been specifically approved by the DCGI for managing uncontrolled hypertension in patients with stable coronary artery disease, making it the world’s first fixed-dose combination of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.

Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals.

North America was the largest region in the peripheral vasodilator drugs market in 2025. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peripheral vasodilator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the peripheral vasodilator drugs market by increasing the cost of imported active pharmaceutical ingredients and chemical intermediates used in drug manufacturing. These impacts are most visible across calcium channel blockers and nitrate-based drugs, particularly in regions dependent on cross-border pharmaceutical supply chains such as North America and Europe. Higher input costs have influenced pricing in hospital and retail pharmacy channels. However, tariffs have also encouraged domestic manufacturing and greater use of locally produced generic vasodilators.

The peripheral vasodilator drugs market research report is one of a series of new reports that provides peripheral vasodilator drugs market statistics, including peripheral vasodilator drugs industry global market size, regional shares, competitors with a peripheral vasodilator drugs market share, detailed peripheral vasodilator drugs market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral vasodilator drugs industry. This peripheral vasodilator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peripheral vasodilator drugs are medications that mainly act on blood vessels located outside the heart and brain, focusing specifically on the peripheral circulation. These medications work by widening (dilating) blood vessels, which decreases resistance to blood flow and helps lower blood pressure.

The main categories of peripheral vasodilator drugs consist of calcium channel blockers, direct-acting vasodilators, alpha-adrenergic blockers, potassium channel activators, nitrates, and others. Calcium channel blockers are drugs that relax and expand blood vessels by preventing calcium from entering the cells of the heart and arterial walls, which helps lower blood pressure and enhance blood circulation. Their indications include hypertension, angina, heart failure, and others, with applications in hospitals, retail pharmacies, and other settings.

The peripheral vasodilator drugs market consists of sales of angiotensin II receptor blockers (ARBs), nitric oxide donors, direct renin inhibitors, and endothelin receptor antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.